AbCellera Biologics (ABCL) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Xeris Biopharma (XERS) over the past year, gaining 176.1% versus a gain of 148.5%. Over five years, XERS leads with a +682.0% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $3.10 billion), about 1.0 times the size.
Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | XERS |
|---|---|---|
| Share price | $9.69 | $16.97 |
| Market cap | $3.16B | $3.10B |
| 1-day change | -7.45% | +2.11% |
| YTD return | +183.33% | +116.18% |
| 1-year return | +176.07% | +148.46% |
| 5-year return | -30.74% | +682.03% |
| Forward P/E | — | 63.64 |
| EPS (TTM) | $-0.48 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $291.85M |
| Revenue growth (YoY) | +160.56% | +43.72% |
| Net income (latest FY) | $-146.41M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | -288.98% | 8.53% |
| Net margin | -194.88% | 0.19% |
| 52-week high | $15.02 | $17.28 |
| 52-week low | $2.75 | $5.25 |
| Distance from 52-week high | -35.46% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +1.89% |
| Average volume | 4.34M | 2.86M |
| Shares outstanding | 326.62M | 182.70M |
| Employees | 562 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed XERS by 27.6 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +43.72%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
ABCL vs XERS FAQ
Which is bigger, AbCellera Biologics or Xeris Biopharma?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $3.10B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, ABCL or XERS?
ABCL returned +176.07% over the past 12 months, compared with +148.46% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.